Zydus Lifesciences reports record FY26 PAT and buyback approval
after close1 source ↓written by the desknot a recommendation
- a margin
- 31.2%
- at ₹1
- ₹1,100 cr share buyback
Zydus Lifesciences reported a consolidated PAT of ₹5,026.4 cr for FY26, achieving a record EBITDA of ₹8,984.6 cr with a margin of 31.2%. The Board approved a ₹1,100 cr share buyback at ₹1,260 per share. This strong performance reflects effective cost management despite challenges from US generics competition.
Not investment advice. For informational purposes only.